Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

Inclusion Criteria: Diagnosis: Patients must have had histologic or cytologic verification of the below qualified malignancy. The pathology report for the diagnosis under which the patient is being enrolled and associated molecular diagnostic reports must be submitted. a. Hodgkin's Lymphoma (HD): Patients with HD are eligible with one of the following: i. Second or greater recurrence or refractory to at least 2 prior therapeutic regimens. ii. Any relapse after HSCT. b. Non-Hodgkin Lymphoma (NHL): Patients with NHL are eligible with one of the following: i. Second or greater recurrence or refractory to at least 2 prior therapeutic regimens. ii. Any relapse after HSCT or CAR T cell therapy. c. Acute Myeloid Leukemia (AML): Patients with AML are eligible with one of the following: i. First or greater relapse. ii. Primary refractory disease with at least 1 prior induction attempts. d. Acute Lymphoblastic Leukemia (ALL): Patients with ALL are eligible with one of the following: i. Second or greater relapse or refractory to at least 2 prior therapeutic regimens. ii. Any relapse after HSCT or CAR T cell therapy. e. Other Hematopoietic malignancy not listed above for which standard curative measures do not exist, are not proven to prolong survival with an acceptable quality of life, or are no longer effective. CD30 Expression Status: Disease specific histologic, cytologic, or Fluorescence-Activated Cell Sorting (FACS)-confirmed CD30 cell surface expression on malignant cells is required. CD30 surface expression must be confirmed at most recent histologic, cytologic, or FACS assessment of disease. This confirmation must occur at recurrence. No repeat CD30 expression verification is required for patients with primary refractory diseases. Pathology and diagnostic reports verifying the CD30 expression status must be submitted. Leukemia CD30 Expression Criteria: Flow cytometry immunophenotypic analysis of bone marrow or peripheral blood. Surface expression of CD30 expression on blasts "positive" with ≥20% expression consistent with established precedents. Lymphoma CD30 Expression Criteria: Flow cytometry immunophenotypic analysis of lymphoma sample or immunohistochemical assessment of formalin-fixed paraffin embedded sample. Flow cytometry assessment surface expression or immunohistochemical membranous expression of CD30 on neoplastic cells "positive" with ≥ 1% expression consistent with established precedents. Disease Status: i. Lymphomas: Patients must have measurable disease for assessment of radiographic response defined as either nodal disease \>/=1.5 cm or extranodal lesion \>/=1.0 cm. ii. Leukemias: Patients must have relapsed/refractory (including MRD \>0.01% by flow cytometry) disease. Prior Therapy: Patients must have recovered from the acute toxic effects of prior anticancer chemotherapy, defined as resolution of all such toxicities to ≤ Grade 2 or lower prior to entering this study and initiating lymphocyte collection. i. Myelosuppressive chemotherapy: Patients must not have received myelosuppressive therapy within 3 weeks of apheresis for this study. ii. Hematopoietic growth factors: At least 14 days after the last dose of a long-acting growth factor (e.g., Neulasta) or 7 days for short-acting growth factor. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair. iii. Biologic (anti-neoplastic agent): At least 7 days after the last of a biologic agent that is not a monoclonal antibody and infusion of study product on this study. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair. iv. Immunotherapy: At least 6 weeks since the completion of any type of immunotherapy, e.g., tumor vaccines or CAR T-cell therapy. v. Monoclonal antibodies: At least 3 half-lives must have elapsed after treatment with a monoclonal antibody and infusion of study product on this study. vi. XRT: \>2 weeks must have elapsed for XRT and infusion of study product. vii. Prior treatment with etoposide, vincristine, CD30 targeted agent, or a bispecific antibody-armed activated autologous T-cell product as single agents or in combination are eligible for this study provided there were no known hypersensitivity or allergic reactions attributed to any of the components of compounds of similar composition to etoposide, vincristine, CD30 targeted agent, or a bispecific Antibody-armed activated autologous T cell product. Age: Patients must be ≥ 18 years at time of study enrollment. Life Expectancy: Life expectance of \>12 weeks. Performance Status: Karnofsky ≥50% for patients. Note: Neurologic deficits in patients with CNS involvement must have been stable for at least 7 days prior to study enrollment. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score. Organ Function Requirements: Have acceptable organ function as defined below: i. Renal: Serum creatinine concentration ≤1.5 × institutional upper limit of normal (ULN) based on the age and sex, or creatinine clearance (CrCl) ≥50 mL/min (as measured by Cockcroft-Gault formula or acceptable equivalent). ii. Hepatic: 1. Direct Bilirubin \<1.5 x upper limit of normal (ULN) for age. For patients with documented Gilbert's syndrome (unconjugated hyperbilirubinemia) the bilirubin must be ≤3 x ULN for age. 2. SGPT (ALT) \<3 x ULN. 3. Serum albumin \>2 g/dL. iii. Pulmonary: Pulse oximetry \>90% on room air. Subjects must have no supplemental oxygen requirement. iv. Cardiac: LVEF ≥ 40% by ECHO or MUGA. v. HL and NHL specific criteria: Bone Marrow: Ad